Full-Time

Senior Manager

Health Systems EMR Integration

Posted on 11/22/2024

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Compensation Overview

$141.6k - $177kAnnually

Senior

Company Historically Provides H1B Sponsorship

Remote in USA

Category
Project Management
Business Development
Business & Strategy
Requirements
  • 4+ years of project management experience, with at least 2+ years doing so for health systems
  • 4+ years of leading large projects and managing teams
  • Deep knowledge of health system interoperability techniques and methods
  • Experience with healthcare integration standards such as HL7, cCDA, FHIR, etc.
Responsibilities
  • Lead and streamline the project management of health systems EMR integration engagements with Natera
  • Regularly report status of integration projects to sales, operations, and project stakeholders, and/or executive leadership team
  • Plan, prioritize, resource, deploy complex EMR integration solutions that deliver exceptional experiences to providers and patients.
  • Collaborate to develop and implement a process for requesting objective and constructive feedback from customers 30/60/90 days post implementation on customer experience during the implementation and their use of the EMR integration
  • Recruit, coach, and manage a team responsible for implementing EMR integrations with health systems
  • Implement and support best project management practices for systems implementations and upgrades.
  • Develop and use deep understanding of Natera’s users to deliver an outstanding user experience.
  • Support sales team in their efforts to present customers the best integrated solutions for their needs
  • Solicit customer feedback and funnel new requirements and product changes back into software development.
  • Coordinate and make available the necessary resources for project managers to use in achieving positive outcomes for all health systems EMR integration projects.
Desired Qualifications
  • Vendor management experience is preferred but not required.

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and monitoring. Their services include the Signatera test for cancer patients, organ health assessments for transplant patients, and various tests for women's health, such as prenatal screening. Natera stands out by offering specialized testing solutions and genetic counseling services, which are often reimbursed by insurance. The company's goal is to provide advanced testing solutions that support patients and healthcare providers in making informed medical decisions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • AI integration enhances accuracy of Natera's genetic tests, improving patient outcomes.
  • Telehealth expansion aligns with Natera's remote genetic counseling services, broadening their reach.

What critics are saying

  • Hindenburg's report accuses Natera of deceptive practices, risking legal and reputational issues.
  • CFO's stock sale may signal internal concerns about Natera's future performance.
  • Reliance on insurance reimbursements poses a risk if policies or rates change.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for prenatal and cancer diagnostics.
  • The company offers the unique Signatera test for personalized cancer monitoring.
  • Natera's Prospera Heart test uses a novel Donor Quantity Score for transplant rejection detection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

9%
Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

INACTIVE